Anzeige
Mehr »
Dienstag, 22.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CM

WKN: A427B1 | ISIN: CA1850536006 | Ticker-Symbol: CWY0
NASDAQ
21.09.26 | 21:35
0,778 US-Dollar
-1,58 % -0,013
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARMIND MEDICINE INC Chart 1 Jahr
5-Tage-Chart
CLEARMIND MEDICINE INC 5-Tage-Chart

Aktuelle News zur CLEARMIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoClearmind Medicine Inc. - 6-K, Report of foreign issuer1
DoClearmind testifies at FDA hearing on psychedelic therapies1
DoClearmind Medicine Inc.: Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.235Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins Vancouver, Canada, Sept....
► Artikel lesen
11.09.Clearmind enrolls first AUD patients in CMND-100 clinical trial3
11.09.Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial409Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived...
► Artikel lesen
10.09.Clearmind Medicine Inc. GAAP EPS of -$0.572
CLEARMIND MEDICINE Aktie jetzt für 0€ handeln
08.09.Clearmind erhält IRB-Zulassung von Yale für Patientenrekrutierung in AUD-Studie-
08.09.Clearmind gets Yale IRB approval for AUD trial enrollment1
08.09.Clearmind Medicine Inc.: Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results179Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company" or "Clearmind"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic...
► Artikel lesen
08.09.Clearmind Medicine Inc. - 6-K, Report of foreign issuer-
04.09.Clearmind Tumbles on Buying into Charging Robotics3
04.09.Clearmind Medicine To Acquire 51% Stake In Charging Robotics For $2.5 Million2
04.09.Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics1
04.09.Clearmind to acquire 51% stake in EV charging firm for $2.5M5
04.09.Clearmind Medicine Inc.: Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis495Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments...
► Artikel lesen
01.09.Clearmind Medicine Inc. - 6-K, Report of foreign issuer1
01.09.Clearmind initiates phase IIa trial for alcohol use disorder drug2
01.09.Clearmind Medicine Inc.: Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled371Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived...
► Artikel lesen
25.08.Neurothera Labs Inc: Neurothera, Clearmind apply for U.S. patent1
24.08.Clearmind Medicine Inc. - 6-K, Report of foreign issuer1
Weiter >>
121 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1